Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
November 2022
in “
The Journal of Urology
”
TLDR Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.
The study explores the potential cost savings for Medicare if it adopted the pricing model of the Mark Cuban Cost Plus Drug Company (MCCPDC) for urological drugs. By analyzing the 9 most utilized oral urology drugs, the study found that MCCPDC's cost-plus pricing could have saved Medicare approximately $1.29 billion in 2020. The savings were significant for 90-day prescriptions, with percentage savings ranging from 48.7% to 99.2%. The study highlights the financial burden of high drug prices on patients and suggests that MCCPDC's model could provide a more affordable option, benefiting both patients and the healthcare system.
